IL272949B2 - Improved treatment of atopic dermatitis with tradipitant - Google Patents
Improved treatment of atopic dermatitis with tradipitantInfo
- Publication number
- IL272949B2 IL272949B2 IL272949A IL27294920A IL272949B2 IL 272949 B2 IL272949 B2 IL 272949B2 IL 272949 A IL272949 A IL 272949A IL 27294920 A IL27294920 A IL 27294920A IL 272949 B2 IL272949 B2 IL 272949B2
- Authority
- IL
- Israel
- Prior art keywords
- biomarker
- tradipitant
- day
- present
- biological sample
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558303P | 2017-09-13 | 2017-09-13 | |
| US201762572456P | 2017-10-14 | 2017-10-14 | |
| PCT/US2018/048825 WO2019055225A1 (en) | 2017-09-13 | 2018-08-30 | ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL272949A IL272949A (en) | 2020-04-30 |
| IL272949B1 IL272949B1 (en) | 2025-03-01 |
| IL272949B2 true IL272949B2 (en) | 2025-07-01 |
Family
ID=63684468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272949A IL272949B2 (en) | 2017-09-13 | 2018-08-30 | Improved treatment of atopic dermatitis with tradipitant |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11549147B2 (enExample) |
| EP (2) | EP3681505B1 (enExample) |
| JP (1) | JP7347743B2 (enExample) |
| KR (2) | KR20250036264A (enExample) |
| CN (1) | CN111093671A (enExample) |
| AU (1) | AU2018331267B2 (enExample) |
| CA (1) | CA3073998A1 (enExample) |
| CL (1) | CL2020000655A1 (enExample) |
| IL (1) | IL272949B2 (enExample) |
| MX (2) | MX2020002852A (enExample) |
| WO (1) | WO2019055225A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102860817B1 (ko) * | 2015-03-04 | 2025-09-16 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피턴트에 의한 치료 방법 |
| CA3101210A1 (en) | 2018-06-08 | 2019-12-12 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| CN115052599A (zh) * | 2020-02-25 | 2022-09-13 | 万达制药公司 | 以川地匹坦对特应性皮炎的改进治疗 |
| US20230145932A1 (en) | 2020-03-26 | 2023-05-11 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| WO2021225303A1 (ko) | 2020-05-07 | 2021-11-11 | 주식회사 엘지에너지솔루션 | 고-니켈 전극 시트 및 이의 제조방법 |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| KR20250123807A (ko) | 2022-12-21 | 2025-08-18 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 치료 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016141341A1 (en) * | 2015-03-04 | 2016-09-09 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263498B (enExample) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| DK1501808T3 (da) | 2002-04-26 | 2008-10-13 | Lilly Co Eli | Tachykininreceptor-antagonister |
| MXPA04010622A (es) | 2002-04-26 | 2005-01-25 | Lilly Co Eli | Derivados de triazol como antagonistas de receptor de taquicinina. |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| BRPI0415010B8 (pt) | 2003-10-24 | 2021-05-25 | Lilly Co Eli | formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| CA2643130A1 (en) | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compounds and methods of treating disorders associated with activation of metachromatic cells |
| JP5443168B2 (ja) | 2006-12-20 | 2014-03-19 | イーライ リリー アンド カンパニー | ｛２−［１−（３，５−ビス−トリフルオロメチル−ベンジル）−５−ピリジン−４−イル−１ｈ−［１，２，３］トリアゾール−４−イル］−ピリジン−３−イル｝−（２−クロロフェニル）−メタノンの調製において有用な新規の中間体及び方法 |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| EP3013336A1 (en) | 2013-06-24 | 2016-05-04 | Tigercat Pharma Inc. | Use of nk-1 receptor antagonist serlopitant in pruritus |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
-
2018
- 2018-08-30 CN CN201880059276.3A patent/CN111093671A/zh active Pending
- 2018-08-30 US US16/644,567 patent/US11549147B2/en active Active
- 2018-08-30 WO PCT/US2018/048825 patent/WO2019055225A1/en not_active Ceased
- 2018-08-30 IL IL272949A patent/IL272949B2/en unknown
- 2018-08-30 KR KR1020257006413A patent/KR20250036264A/ko active Pending
- 2018-08-30 JP JP2020515146A patent/JP7347743B2/ja active Active
- 2018-08-30 CA CA3073998A patent/CA3073998A1/en active Pending
- 2018-08-30 MX MX2020002852A patent/MX2020002852A/es unknown
- 2018-08-30 EP EP18778635.5A patent/EP3681505B1/en active Active
- 2018-08-30 AU AU2018331267A patent/AU2018331267B2/en active Active
- 2018-08-30 KR KR1020207010029A patent/KR20200054232A/ko not_active Ceased
- 2018-08-30 EP EP24211922.0A patent/EP4487912A3/en active Pending
-
2020
- 2020-03-12 CL CL2020000655A patent/CL2020000655A1/es unknown
- 2020-03-13 MX MX2024004377A patent/MX2024004377A/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016141341A1 (en) * | 2015-03-04 | 2016-09-09 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4487912A3 (en) | 2025-03-26 |
| US20210062262A1 (en) | 2021-03-04 |
| KR20200054232A (ko) | 2020-05-19 |
| CN111093671A (zh) | 2020-05-01 |
| RU2020112222A (ru) | 2021-10-13 |
| KR20250036264A (ko) | 2025-03-13 |
| JP2020533381A (ja) | 2020-11-19 |
| EP3681505B1 (en) | 2024-12-18 |
| CA3073998A1 (en) | 2019-03-21 |
| MX2024004377A (es) | 2024-04-26 |
| EP3681505A1 (en) | 2020-07-22 |
| EP3681505C0 (en) | 2024-12-18 |
| BR112020004964A2 (pt) | 2020-09-15 |
| AU2018331267B2 (en) | 2024-03-07 |
| EP4487912A2 (en) | 2025-01-08 |
| IL272949B1 (en) | 2025-03-01 |
| WO2019055225A1 (en) | 2019-03-21 |
| US11549147B2 (en) | 2023-01-10 |
| JP7347743B2 (ja) | 2023-09-20 |
| IL272949A (en) | 2020-04-30 |
| AU2018331267A1 (en) | 2020-04-16 |
| MX2020002852A (es) | 2020-07-22 |
| CL2020000655A1 (es) | 2020-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272949B2 (en) | Improved treatment of atopic dermatitis with tradipitant | |
| Wikramanayake et al. | Seborrheic dermatitis—looking beyond Malassezia | |
| Ha et al. | Huntington's disease | |
| Santos et al. | Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid | |
| Mount | The kidney in hyperuricemia and gout | |
| Peters et al. | Carnosine treatment in combination with ACE inhibition in diabetic rats | |
| JP2020533381A5 (enExample) | ||
| Syu et al. | Severe exercise and exercise training exert opposite effects on human neutrophil apoptosis via altering the redox status | |
| WO2009073544A3 (en) | Methods for treating a disorder by regulating gprc6a | |
| Zhang et al. | β-Casomorphin-7 attenuates the development of nephropathy in type I diabetes via inhibition of epithelial–mesenchymal transition of renal tubular epithelial cells | |
| Hansen et al. | The lung inflammation and skeletal muscle wasting induced by subchronic cigarette smoke exposure are not altered by a high-fat diet in mice | |
| Shen et al. | Phosphate–Induced Renal Fibrosis Requires the Prolyl Isomerase Pin1 | |
| Wang et al. | Roseotoxin B improves allergic contact dermatitis through a unique anti-inflammatory mechanism involving excessive activation of autophagy in activated T lymphocytes | |
| Căluianu et al. | Assessment of T-and B-lymphocytes and VEGF-A in acute pancreatitis | |
| RU2022114399A (ru) | Усовершенствованное лечение атопического дерматита традипитантом | |
| Nawaz et al. | Alternate‐day fasting enhanced weight loss and metabolic benefits over pair‐fed calorie restriction in obese mice | |
| WO2020056155A3 (en) | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease | |
| WO2020206115A3 (en) | Angptl2 antisense oligonucleotides and uses thereof | |
| Ke et al. | Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis | |
| Mucke et al. | OP0141 TREAT TO TARGET IN SYSTEMIC LUPUS ERYTHEMATOSUS FROM THE PATIENTS'PERSPECTIVE–RESULTS FROM AN INTERNATIONAL PATIENT SURVEY | |
| Rao et al. | Successful treatment of tuberous sclerosis with psychosis and obsessive-compulsive disorder: A case report. | |
| Xu et al. | A2544 Effect of hyperhomocysteine on the renal damage of hypertensive rats and the mechanism of enalapril folic acid intervention | |
| Ammar et al. | Diet Quality, Malnutrition Risk and Micronutrient (Magnesium and Vitamin D) Profile among COVID-19 Survivors: A Post-Recovery Follow-Up Study | |
| Ramos-Lopez et al. | Association of Two Novel Bitter Taste Receptor 2R38 (TAS2R38) Haplotypes with Alcohol Intake among the Population of West Mexico: 1201 | |
| NZ783656A (en) | Tasimelteon use in treating sleep aberrations |